RxDoctor Payments Data

Ankur Patel, MD

Family Medicine · Dorchester, MANPI 1932580495

Payments from drug & device makers

$3,524in general payments, 2019–2025

Across 202 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$539
  • Lilly USA, LLC$524
  • Pfizer$382
  • Takeda Pharmaceuticals U.S.A., Inc.$227
  • Amgen$225
  • Johnson & Johnson$204
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,524100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,524 in reported general payments places this provider in the 90th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$24,150
Medicare patients
76
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$60,454
EliquisApixaban51$52,525
FarxigaDapagliflozin Propanediol34$36,055
TrulicityDulaglutide26$24,987
JardianceEmpagliflozin13$20,973
JanuviaSitagliptin Phosphate12$19,062
Varenicline Tartrate14$4,994
Atorvastatin Calcium304$3,671
Omeprazole190$3,549
SymbicortBudesonide/Formoterol Fumarate13$3,156
Niacin ErNiacin21$2,781
DilantinPhenytoin Sodium Extended15$2,547
Rosuvastatin Calcium129$2,241
Lidocaine21$2,049
Metoprolol Succinate136$1,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$165$60,45452 claims
PfizerEliquis, Dilantin$382$55,07266 claims
AstraZenecaFarxiga, Symbicort$201$39,21147 claims
Lilly USA, LLCTrulicity$524$24,98726 claims
Boehringer IngelheimJardiance$123$20,97313 claims
MerckJanuvia$107$19,06212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Dorchester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →